DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$30.06+7.36%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · DMRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -29.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
DMRA — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-07-20
Material Modification to Rights of Security Holders. The Company held a special meeting on February 9, 2026 (the “ Special Meeting ”) to approve all of the proposals in its definitive proxy statement filed on Form DEF 14A with the U.S. Securities and Exchange Commission (the “ SEC ”) on December 31, 2025 (the “ Proxy Statement ”). At the Special Meeting, the Company’s stockholders approved, among other matters, the redomestication of the Company from the State of Delaware to the Cayman Island…
Why it matters: The recent capital raise is vital for liquidity. Investors need to see if it supports ongoing operations.
Supportive ifLiquidity is better. Cash and equivalents are over $600 million in Q2.
Worry ifLiquidity drops below $500 million in the next report.
Why it matters: High losses mean cash flow problems and issues for management.
Worry ifQ2 losses are worse than $30 million.
Less concerning ifLosses are below $30 million. This shows better cost management.
Why it matters: News on clinical programs shows how Damora is working to treat blood disorders. This may affect how investors feel.
Supportive ifAt least one clinical program must start by the end of 2026.
Worry ifNo clinical programs can start by the end of 2026.
Why it matters: News on cash flow will show if the money raised is enough for operations.
Watch forCash flow is over $535 million. This shows good money management.
Also watch forCash flow is under $535 million. This raises worries about financial health.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$256 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $1,287 loss on $10,000 · 12.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,238 loss on $10,000 · 72.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The new CEO and CFO are key to the company's future. Their effectiveness will impact strategy and execution.
Supportive ifManagement shares a new plan or partnership. This shows the new leaders are effective.
Worry ifOngoing problems or bad news show the leaders are not effective.
Why it matters: Changes in cash levels can impact the company's ability to fund operations and clinical trials. This is crucial for financial health.
Worry ifCash and cash equivalents drop from $535 million as of February 2026.
Less concerning ifCash and cash equivalents stay stable or increase. This shows better financial management.
Why it matters: Persistent cash burn indicates financial health. Investors need to see if cash flow improves.
Worry ifCash from operations improves to less than negative $20 million in Q2.
Less concerning ifCash from operations remains negative and worsens in Q2.
Why it matters: The new CFO's approach will be key to managing cash flow and losses. This could stabilize the company.
Supportive ifThe company says cash flow is better. Operating losses are lower in the next quarter.
Worry ifOperating losses get worse. Cash flow stays negative after the new CFO starts.
Why it matters: The CFO leaving creates uncertainty for the company's leaders. Stability is key for investor trust.
Worry ifA new CFO is appointed and remains in the role for at least two consecutive quarters.
Less concerning ifAnother executive leaves or the new CFO departs within six months.
Why it matters: Better cash flow is important. It helps keep operations running and funds new projects.
Supportive ifCash from operations becomes positive in Q2 2026. This shows better cash management.
Worry ifCash from operations stays negative or gets worse compared to Q1 2026.